Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1206531-53-4

Post Buying Request

1206531-53-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1206531-53-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1206531-53-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,6,5,3 and 1 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1206531-53:
(9*1)+(8*2)+(7*0)+(6*6)+(5*5)+(4*3)+(3*1)+(2*5)+(1*3)=114
114 % 10 = 4
So 1206531-53-4 is a valid CAS Registry Number.

1206531-53-4Downstream Products

1206531-53-4Relevant articles and documents

Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30

Ramesh, Chinnasamy,Nayak, Tapan K.,Burai, Ritwik,Dennis, Megan K.,Hathaway, Helen J.,Sklar, Larry A.,Prossnitz, Eric R.,Arterburn, Jeffrey B.

, p. 1004 - 1014 (2010)

A series of iodo-substituted tetrahydro-3H-cyclopenta[c]quinolines was synthesized as potential targeted imaging agents for the G protein-coupled estrogen receptor GPR30. The affinity and specificity of binding to GPR30 versus the classical estrogen receptors ERR/β and functional responses associated with ligand-binding were determined. Selected iodo-substituted tetrahydro-3H-cyclopenta-[c]quinolines exhibited IC50 values lower than 20 nM in competitive binding studies with GPR30-expressing human endometrial cancer cells. These compounds functioned as antagonists of GPR30 and blocked estrogen-induced PI3K activation and calcium mobilization. The tributylstannyl precursors of selected compounds were radiolabeled with 125I using the iodogen method. In vivo biodistribution studies in female ovariectomized athymic (NCr) nu/nu mice bearing GPR30-expressing human endometrial tumors revealed GPR30-mediated uptake of the radiotracer ligands in tumor, adrenal, and reproductive organs. Biodistribution and quantitative SPECT/CT studies revealed structurally related differences in the pharmacokinetic profiles, target tissue uptake, and metabolism of the radiolabeled compounds as well as differences in susceptibility to deiodination. The high lipophilicity of the compounds adversely affects the in vivo biodistribution and clearance of these radioligands and suggests that further optimization of this parameter may lead to improved targeting characteristics. 2009 American Chemical Society.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1206531-53-4